Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
15 March 2018Website:
http://www.arcusbio.comNext earnings report:
07 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Thu, 31 Oct 2024 22:14:46 GMTDividend
Analysts recommendations
Institutional Ownership
RCUS Latest News
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today presented the first clinical activity data for casdatifan, a HIF-2a inhibitor with best-in-class potential, in an oral plenary session by Dr. Toni K. Choueiri, Dana-Farber Cancer Institute at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics i.
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted four new employees options to purchase a total of 24,100 shares of the Company's common stock at an exercise price per share of $17.47, which was the closing price on October 8, 2024, and.
Arcus Biosciences develops late-stage immunotherapies, with Domvanalimab and Casdastifan leading the way in targeting large oncology markets. Domvanalimab, a Phase 3 anti-TIGIT antibody for NSCLC and GI cancers, could significantly impact treatment upon approval. Casdastifan is advancing to Phase 3 for renal cell carcinoma and may outperform Merck's Belzutifan.
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted three new employees options to purchase a total of 21,100 shares of the Company's common stock at an exercise price per share of $18.01, which was the closing price on August 23, 2024, and.
Domvanalimab shows promising results in gastric cancer, with a 56% response rate and median progression-free survival of 12.9 months. Quemlicustat sees progress with Taiho exercising rights in Asia, while etrumadenant shows positive results in colorectal cancer trials. Arcus Biosciences pipeline continues to show potential, but TIGIT failures in the industry pose a significant risk to the company's outlook.
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted two new employees options to purchase a total of 3,500 shares of the Company's common stock at an exercise price per share of $16.41, which was the closing price on June 24, 2024, and rest.
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted six new employees options to purchase a total of 36,100 shares of the Company's common stock at an exercise price per share of $16.09, which was the closing price on June 10, 2024, and res.
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced the completion of patient enrollment for STAR-221, a Phase 3 study in collaboration with Gilead Sciences, evaluating the combination of the Fc-silent anti-TIGIT antibody domvanalimab plus the anti-PD-1 monoclonal antibody zimberelimab and chemotherapy in patients.
Investors need to pay close attention to Arcus Biosciences (RCUS) stock based on the movements in the options market lately.
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted three new employees options to purchase a total of 16,300 shares of the Company's common stock at an exercise price per share of $16.28, which was the closing price on May 23, 2024, and re.
What type of business is Arcus Biosciences?
Arcus Biosciences Inc is a biopharmaceutical company operating in the clinical stage. It is developing immunotherapy for the treatment of cancer. The company focuses on the adenosine triphosphate (ATP)-adenosine pathway, which is a key factor in immunosuppression in the tumor microenvironment, to create and optimize differentiated low molecular weight candidate drugs for immuno-oncology. Its product pipeline includes Domvanalimab, Etrumadenant, AB680 and Zimberelimab. Arcus is conducting clinical trials for various types of cancer, such as prostate cancer, lung cancer, colorectal cancer, pancreatic cancer, and others. The company operates in a single segment, focusing on the development and commercialization of immunotherapeutic drugs. The company was founded in 2015 and is based in Hayward, California.
What sector is Arcus Biosciences in?
Arcus Biosciences is in the Healthcare sector
What industry is Arcus Biosciences in?
Arcus Biosciences is in the Biotechnology industry
What country is Arcus Biosciences from?
Arcus Biosciences is headquartered in United States
When did Arcus Biosciences go public?
Arcus Biosciences initial public offering (IPO) was on 15 March 2018
What is Arcus Biosciences website?
https://www.arcusbio.com
Is Arcus Biosciences in the S&P 500?
No, Arcus Biosciences is not included in the S&P 500 index
Is Arcus Biosciences in the NASDAQ 100?
No, Arcus Biosciences is not included in the NASDAQ 100 index
Is Arcus Biosciences in the Dow Jones?
No, Arcus Biosciences is not included in the Dow Jones index
When was Arcus Biosciences the previous earnings report?
No data
When does Arcus Biosciences earnings report?
The next expected earnings date for Arcus Biosciences is 07 November 2024